LZTR1 knockdown increased RAS protein expression in LOVO but had no effect on the other cell lines (Fig. 4L, S4G), consistent with our cycloheximide data demonstrating that LOVO had an intermediate RAS stability between the adenocarcinoma and hematologic cancer lines (Fig. 4J). Here, LZTR1 is linked to hematopoietic and lymphoid cell neoplasm.